Life after charge noise: recent results with transmon qubits

We review the main theoretical and experimental results for the transmon, a superconducting charge qubit derived from the Cooper pair box. The increased ratio of the Josephson to charging energy results in an exponential suppression of the transmon's sensitivity to 1/f charge noise. This has been observed experimentally and yields homogeneous broadening, negligible pure dephasing, and long coherence times of up to 3 microseconds. Anharmonicity of the energy spectrum is required for qubit operation, and has been proven to be sufficient in transmon devices. Transmons have been implemented in a wide array of experiments, demonstrating consistent and reproducible results in very good agreement with theory.Comment: 6 pages, 4 figures. Review article, accepted for publication in Quantum Inf. Pro

Characterization of the atmosphere of TRAPPIST-1 e with JWST and ELT

Stars and planetary system

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

To explore the effects of immunotherapy in the International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts were studied: one prior to and one after the introduction of dinutuximab beta. All patients received standard induction and high-dose therapy (HDT) with autologous stem cell rescue (ASCR); the local control comprised surgery and radiotherapy to the primary tumour site, followed by isotretinoin. A landmark timepoint of 109 days, resulting from the median time between ASCR and initiation of immunotherapy, was used to define patients’ eligibility in the pre-immunotherapy analysis cohort. Median follow-up was 5.8 years (inter-quartile range (IQR): 4.2–8.2 years) for 844 eligible patients balanced for risk factors, such as age, sex, stage 4, MYCN amplification and response prior to HDT. The five-year event-free and overall survival (95% confidence interval (CI) of 466 patients not receiving immunotherapy was 42% (38–47%) and 50% (46–55%) but was 57% (51–62%) and 64% (59–69%) for 378 patients receiving immunotherapy (p 1 metastatic compartment at diagnosis (p < 0.001, HR 2.665) as risk factors for relapse or progression. Results suggest an important role for dinutuximab beta-based immunotherapy within the treatment concepts applied in HR- NBL1/SIOPEN

Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity

10.1186/s13395-020-00227-4Skeletal Muscle101